Терапевтический архив (Jul 2021)

Li–Fraumeni syndrome in adult patients with acute lymphoblastic leukemia

  • Kseniia I. Zarubina,
  • Elena N. Parovichnikova,
  • Vadim L. Surin,
  • Olesia S. Pshenichnikova,
  • Olga A. Gavrilina,
  • Galina A. Isinova,
  • Vera V. Troitskaya,
  • Andrei N. Sokolov,
  • Irina V. Galtseva,
  • Nikolai M. Kapranov,
  • Juliia O. Davydova,
  • Tatiana N. Obukhova,
  • Elena E. Nikulina,
  • Andrei B. Sudarikov,
  • Valerii G. Savchenko

DOI
https://doi.org/10.26442/00403660.2021.07.200913
Journal volume & issue
Vol. 93, no. 7
pp. 763 – 769

Abstract

Read online

Background. LiFraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary disorder that is characterized by an increased risk for certain types of cancer, acute lymphoblastic leukemia (ALL), particularly. Germline TP53 mutations are associated with LFS. Genetic counseling and follow-up is essential for patients with LFS and their relatives. Special therapeutic approaches are needed for treatment of oncological disease in these patients. The article presents a series of clinical cases of patients with ALL and SLF, considers general issues of diagnosis and treatment of adult patients with this hereditary genetic syndrome. Aim. Describe clinical observations of patients with acute lymphoblastic leukemia (ALL) and LFS and consider general issues of diagnosis and treatment of adult patients with LFS and ALL. Materials and methods. TP53 gene mutations were screened using Sanger sequencing in 180 de novo patients with Ph-negative (B- and T-cell) and Ph-positive ALL treated by Russian multicenter protocols (ALL-2009, ALL-2012, ALL-2016) at the National Research Center for Hematology, Moscow, Russia, and at the hematology departments of regional clinics of Russia (multicenter study participants). Results. TP53 gene mutations were found in 7.8% (n=14) of de novo ALL patients. In patients, whose biological material was available TP53 gene mutational status was determined in non-tumor cells (bone marrow and peripheral blood during remission, bone marrow samples after allogeneic hematopoietic stem cells transplantation and in tissue of non-hematopoietic origin) for discriminating germline mutations. The analysis included 5 patients (out of 14 with TP53 mutations), whose non-tumor biological material was available for research. Germline status was confirmed in 4 out of 5 B-cell ALL (n=3), T-cell ALL (n=1) investigated patients. Conclusion. Practical value of the research is the observation that the greater part of TP53 gene mutations in patients with Ph-negative B-cell ALL are germinal and associated with LFS.

Keywords